Back

Potent P2Y12 inhibition with ticagrelor over clopidogrel in complex PCI: a systematic review and meta-analysis of clinical outcomes

31 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Optimising outcomes in percutaneous coronary intervention: risk assessment, pharmacotherapy, and clinical insights Adjunctive Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Andre Dos Santos Cleto

HAOC - Hospital Augusto de Oliveira Camargo, Indaiatuba (Brazil)

5 More presentations in this session

Presentation thumbnail
CKD severity and high bleeding risk in patients undergoing PCI: stage-specific validation of modified ARC-HBR criteria
Doctor F. Di Muro (Salerno, IT)
Abstract
Presentation thumbnail
Association of ANGPTL3, ANGPTL4, and DOCK7 polymorphisms with lipid traits and long-term clinical outcomes in patients undergoing PCI
Doctor Y. Song (Beijing, CN)
Abstract
Presentation thumbnail
Early bleeding risk prediction with the PRECISE-HBR score in PCI patients treated with cangrelor: the ICARUS registry
Doctor V. De Sio (Caserta, IT)
Abstract
Presentation thumbnail
Perfusion balloon prolonged inflation in lipid-rich coronary lesions and slow flow/no-reflow: NIRS-IVUS insights
Doctor S. Izumoto (Miyazaki, JP)
Abstract
Presentation thumbnail
Women demonstrate better one-year survival than men after microaxial pump-supported high-risk PCI
Associate Professor J. Sacha (Opole, PL)
Abstract

Access the full session

Session thumbnail
Optimising outcomes in percutaneous coronary intervention: risk assessment, pharmacotherapy, and clinical insights

The Event

Event poster

ESC Congress 2026

31 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Real world outcomes for clopidogrel versus ticagrelor treated patients with acute coronary syndrome: a systematic literature review and meta-analysis
2 September 2019
thumbnail
Congress Presentation
Ticagrelor versus clopidogrel for complex percutaneous coronary intervention in chronic coronary syndrome: a post-hoc analysis of the ALPHEUS study
26 August 2023
thumbnail
Congress Presentation
Systematic review and meta analysis of clinical effectiveness safety and midterm recurrence of ventricular pulsed field ablation
14 April 2026
thumbnail
Congress Presentation
Selatogrel, the reversible and specific P2Y12 receptor antagonist, does not interfere with haemostasis
1 September 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources